China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Britain Courts Anthropic Amid US Defense Department Dispute 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
SAN DIEGO, Nov. 30, 2016 -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the BMO Capital Markets Prescription for Success Healthcare Conference in New York City on Wednesday, December 14, 2016 at 10:30 a.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 90 days.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.
Contact: Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 [email protected]
